12:11 PM EST - Abattis Bioceuticals Corp. : Announced it has completed its acquisition of Green Tree Therapeutics. As a result of the Acquisition, Green Tree is now a wholly-owned subsidiary of Abattis and Green Tree’s products will become available through Abattis’s wholly-owned subsidiary Vergence Naturals Ltd. In connection with the Acquisition, the Company issued an aggregate of 15,000,000 common shares of the Company to the former shareholders of Green Tree. In addition, in consideration for the right to acquire Green Tree, which right was previously held by Winston Resources Inc., Abattis issued 15,000,000 Shares to Winston. The Shares issued to Winston are subject to a hold period expiring May 25, 2018. Abattis Bioceuticals Corp.
shares ATT:CNX are trading off 2 cents at $0.67.
